Figure 1From: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaKaplan-Meier survival analysis for all clinical evaluation committee (CEC) community-acquired pneumonia (CAP) patients. P value = 0.25.Back to article page